secwatch.observer — SEC 8-K summary
======================================

Issuer:     Relay Therapeutics, Inc. (RLAY)
CIK:        0001812364
Form:       8-K
Filed at:   2023-08-08T23:59:59+00:00
Accession:  0000950170-23-039822
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Relay Therapeutics Q2 net loss $98.5M; RLY-2608 dose expansion initiated with 86% CBR
--------------------------------------------------------------------------------

- Net loss of $98.5M ($0.81/share) in Q2 2023, up from $76.8M loss ($0.71) in Q2 2022; R&D expenses rose to $88.2M.
- Cash and investments $871.6M as of June 30, 2023; expected to fund operations into H2 2025.
- Initiated RLY-2608 600mg BID + fulvestrant dose expansion; interim CBR 86% (6/7 evaluable pts) with 1 partial response.
- No Grade 3+ hyperglycemia/diarrhea or AE-related discontinuations across 43 breast cancer patients; next data update in 2024.
- Anticipated milestones: RLY-4008 pivotal cohort enrollment H2 2023, ERα degrader candidate nomination 2023, RLY-2139 start early 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1812364/000095017023039822/0000950170-23-039822-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1812364/000095017023039822/rlay-20230808.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-039822

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer